Dr. Lee on Treatment Options mRCC

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with relapsed/refractory metastatic renal cell carcinoma (mRCC).

Currently, the treatment landscape of mRCC is made up of 3 main classes of agents, says Lee.

TKIs and monoclonal antibodies have antiangiogenic effects, says Lee. Bevacizumab (Avastin) is an approved monoclonal antibody with clinical utility.

mTOR-targeted agents are another class of agents that alter the metabolism of the cancer, explains Lee.

While immune checkpoint inhibitors have demonstrated efficacy in the frontline setting, they may be utilized in the relapsed/refractory setting for patients who did not previously receive a checkpoint inhibitor, concludes Lee.